In early April Nobilis Therapeutics will present the results of its clinical trial of NBTX-001 in patients with Panic Disorder at the annual conference of Anxiety and Depression Association of America (ADAA). This is the first documented study of xenon-based therapeutic in patients with psychiatric disorder. The study was published in the Journal of Translational Medicine in June of 2017.